PuraStat
Commercial- Indications
- Gastrointestinal bleeding, Cardiovascular bleeding
Company intelligence / Profile preview
3-D Matrix has commercialized self‐assembling peptide-based medical devices such as PuraStat for bleeding management during surgery and endoscopic procedures. Its hydrogel platform, PuraMatrix, supports regenerative medicine research and cell therapy. The company’s technologies are validated by global use and regulatory certifications. Clinical results indicate effectiveness of their products in managing bleeding during various medical procedures; further clinical development continues to expand indications.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on 3-D Matrix.